NYSE:JNJPharmaceuticals
Johnson & Johnson (JNJ) Could Be 33% Below Fair Value Following OTTAVA FDA Clearance
Johnson & Johnson (JNJ) has moved into U.S. soft tissue robotic surgery after the FDA granted De Novo authorization for its OTTAVA Robotic Surgical System, a table-integrated platform cleared for multiple general surgery procedures.
See our latest analysis for Johnson & Johnson.
Against this backdrop, Johnson & Johnson’s share price has climbed steadily, with a 30 day share price return of 8.44% and a year to date share price return of 25.04%. The 1 year total shareholder return of 56.73%...